Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 861905-97-7 | MDL No. : | MFCD08277258 |
Formula : | C6H9BClNO2 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | RRPKICOTZKTBAG-UHFFFAOYSA-N |
M.W : | 173.41 | Pubchem ID : | 46739024 |
Synonyms : |
|
Num. heavy atoms : | 11 |
Num. arom. heavy atoms : | 6 |
Fraction Csp3 : | 0.17 |
Num. rotatable bonds : | 1 |
Num. H-bond acceptors : | 3.0 |
Num. H-bond donors : | 2.0 |
Molar Refractivity : | 45.99 |
TPSA : | 53.35 Ų |
GI absorption : | High |
BBB permeant : | No |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.68 cm/s |
Log Po/w (iLOGP) : | 0.0 |
Log Po/w (XLOGP3) : | 0.96 |
Log Po/w (WLOGP) : | -0.13 |
Log Po/w (MLOGP) : | -0.66 |
Log Po/w (SILICOS-IT) : | -0.77 |
Consensus Log Po/w : | -0.12 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 1.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -1.86 |
Solubility : | 2.41 mg/ml ; 0.0139 mol/l |
Class : | Very soluble |
Log S (Ali) : | -1.67 |
Solubility : | 3.73 mg/ml ; 0.0215 mol/l |
Class : | Very soluble |
Log S (SILICOS-IT) : | -1.27 |
Solubility : | 9.25 mg/ml ; 0.0533 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 1.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 1.61 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With sodium hydrogencarbonate In water; isopropyl alcohol at 150℃; for 0.25h; Microwave irradiation; | 82 A mixture of (2-methyl-4-pyridinyl)boronic acid hydrochloride (20mg), 3-(3-bromo-1H-indazol-6-yl)-/V-ethyl-5-fluoro-4-methylbenzamide (Intermediate 55, 38mg), sodium hydrogen carbonate (1.5ml) and tetrakis(triphenylphosphine) palladium(O) (5mg) in isopropanol (1ml) in a sealed vessel was heated at 150°C in a microwave oven for 15min. The crude mixture was applied to an SCX cartridge (silica) and eluted with 10% aqueous ammonia (0.88) in methanol. The solvent was evaporated and the residue was purified by preparative HPLC to give the title compound (10.1mg). |
[ 579476-63-4 ]
(2-Methylpyridin-4-yl)boronic acid
Similarity: 0.98
[ 846548-44-5 ]
(2,6-Dimethylpyridin-4-yl)boronic acid
Similarity: 0.86
[ 659742-21-9 ]
(6-Methylpyridin-3-yl)boronic acid
Similarity: 0.82
[ 170230-27-0 ]
(4-(Pyridin-2-yl)phenyl)boronic acid
Similarity: 0.79
[ 579476-63-4 ]
(2-Methylpyridin-4-yl)boronic acid
Similarity: 0.98
[ 846548-44-5 ]
(2,6-Dimethylpyridin-4-yl)boronic acid
Similarity: 0.86
[ 659742-21-9 ]
(6-Methylpyridin-3-yl)boronic acid
Similarity: 0.82
[ 170230-27-0 ]
(4-(Pyridin-2-yl)phenyl)boronic acid
Similarity: 0.79